QC
CRVS icon

Quantessence Capital’s Corvus Pharmaceuticals CRVS Stock Holding History

Quantessence Capital’s Portfolio CRVS Stock Details CRVS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-36,421
Closed -$116K – 245
2025
Q1 		$116K Buy
+36,421
New +$172K 0.03% 303

Other funds holding CRVS

O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
ASP
Adams Street Partners Chicago, Illinois $260M AUM 30.38% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
FCMV
Foresite Capital Management VI Larkspur, California $460M AUM 261.77% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Quantessence Capital's CRVS Position: Q2 2025 in Review

Quantessence Capital sold out of Corvus Pharmaceuticals (CRVS) in Q2 2025, closing a stake of 36,421 shares — an estimated $116K sold.

Quantessence Capital first reported a position in CRVS in Q1 2025 and held it in 1 quarter. The position peaked at $116K in Q1 2025. 92 funds tracked by Wall St. Rank hold CRVS as of Q2 2025.

  • Quantessence Capital reported no remaining Corvus Pharmaceuticals position as of Q2 2025 after selling out during the quarter.
  • Quantessence Capital sold 36,421 Corvus Pharmaceuticals shares in Q2 2025, an estimated $116K.
  • Quantessence Capital first reported a position in Corvus Pharmaceuticals in Q1 2025 and held it in 1 quarter.
  • Quantessence Capital's Corvus Pharmaceuticals position peaked at $116K in Q1 2025.
  • 92 funds tracked by Wall St. Rank held Corvus Pharmaceuticals as of Q2 2025.

Based on Quantessence Capital's 13F filing for Q2 2025, filed 14 Aug 2025.